The U.S. is finally getting a new, better sunscreen ingredient. Today the Food and Drug Administration added bemotrizinol, an effective chemical filter that’s been used in sunscreens made in Asia and ...

Dr. Finucane is a professor of social and behavioral science at Stony Brook University. See more of our coverage in your search results.Encuentra más de nuestra cobertura en los resultados de búsqueda ...

I just returned from a medtech conference, Medtech MVP in Minneapolis, focused on one of the most pressing challenges facing medical device innovators, clinicians, investors, and patients today: the ...

The Trump administration is officially conducting an investigation into the safety of the abortion pill mifepristone, the Wall Street Journal reports. Health experts worry that the process may be ...

This folder contains a lightweight raw-data audit utility for screening tabular scientific datasets before public release, review, or internal quality control. If you use this tool in academic work, ...

This work was supported in part with funding and products provided by Olympus Corporation of the Americas. Although the agreement states a Sponsored Research Agreement, Olympus is funding, but not ...

The US Food and Drug Administration (FDA) has proposed guidance on the types of scientifically valid prior knowledge sponsors should consider when developing certain gene therapies (GT). The agency ...

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors ...

Revolution Medicines and its RAS inhibitor daraxonrasib stole the show at the American Society of Clinical Oncology’s annual meeting this weekend, as Truist Securities predicts a possible third ...

Abstract: Accurate prediction of Drug–Drug Interactions (DDIs) is critical for reducing adverse drug reactions and ensuring safe combination therapies. However, existing benchmarks for DDI prediction ...

Nivolumab (Opdivo, BMS) and pembrolizumab (Keytruda, MSD) are both PD-1 inhibitors approved for multiple oncology indications. While their mechanisms are similar, differences in molecular structure, ...